EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

PubWeight™: 16.93‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 22424438)

Published in J Hepatol on April 01, 2012

Authors

European Association For The Study Of The Liver1, European Organisation For Research And Treatment Of Cancer

Author Affiliations

1: EASL Office, 7 rue des Battoirs, CH-1205 Geneva, Switzerland. easloffice@easloffice.eu

Associated clinical trials:

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study (ROLFH) | NCT01831037

Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial (CAUTIOUS) | NCT03551444

Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma | NCT04414956

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment | NCT04552236

Role of LncRNA H19 in The Regulation of IGF-1R Expression | NCT04767750

Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma (AP-LAPO) | NCT04852211

Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | NCT05161143

Articles citing this

(truncated to the top 100)

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26

Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) (2015) 1.88

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84

Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol (2015) 1.78

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature (2016) 1.71

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer (2016) 1.70

Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun (2014) 1.66

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int (2015) 1.59

Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59

Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer (2012) 1.58

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57

Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol (2015) 1.47

Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol (2015) 1.43

Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis. Medicine (Baltimore) (2014) 1.41

Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39

Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg (2017) 1.36

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer (2014) 1.35

CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology (2014) 1.33

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer (2012) 1.27

Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology (2013) 1.23

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23

Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol (2014) 1.21

Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer (2013) 1.21

Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol (2014) 1.18

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer (2013) 1.17

Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17

Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.17

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol (2016) 1.16

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol (2014) 1.16

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology (2016) 1.15

Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. Am J Gastroenterol (2016) 1.15

The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol (2013) 1.15

Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14

2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14

Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology (2014) 1.14

Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell (2014) 1.13

The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer (2013) 1.13

Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol (2014) 1.12

The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12

Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer (2015) 1.12

Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol (2013) 1.11

Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.11

Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. HPB (Oxford) (2013) 1.10

Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10

Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer (2015) 1.10

How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer (2014) 1.10

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol (2012) 1.09

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist (2014) 1.09

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08

Recent Advances in Tumor Ablation for Hepatocellular Carcinoma. Liver Cancer (2015) 1.08

Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer (2014) 1.07

Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06

Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol (2014) 1.06

Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06

Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06

Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol (2012) 1.06

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res (2012) 1.05

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer (2013) 1.05

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol (2013) 1.04

Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res (2014) 1.03

Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol (2014) 1.03

Drug therapy for advanced-stage liver cancer. Liver Cancer (2014) 1.03

Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02

Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer (2015) 1.01

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) (2015) 1.01

Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01

The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg (2014) 1.01

Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol (2013) 1.01

Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging (2013) 1.00

CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00

Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00

Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One (2013) 1.00

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer (2013) 1.00

Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 1.00

Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget (2015) 0.99

Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One (2014) 0.98

Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98

Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98

Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer (2012) 0.98

Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One (2014) 0.98

Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98

The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One (2013) 0.97

Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97

Staging of hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.97

Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97

Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer (2015) 0.96

Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol (2013) 0.96

Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol (2012) 0.96

Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol (2014) 0.96

Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96

Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg (2015) 0.96

Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol (2014) 0.96

Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol (2014) 0.96

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer (2015) 0.95

Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci (2015) 0.95